These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 15476701

  • 1. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H, Sarre S, Ebinger G, Michotte Y.
    Brain Res; 2004 Nov 05; 1026(1):95-107. PubMed ID: 15476701
    [Abstract] [Full Text] [Related]

  • 2. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H, Sarre S, Ebinger G, Michotte Y.
    J Neurosci Methods; 2005 May 15; 144(1):35-45. PubMed ID: 15848237
    [Abstract] [Full Text] [Related]

  • 3. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
    Moroz IA, Peciña S, Schallert T, Stewart J.
    Exp Neurol; 2004 Sep 15; 189(1):78-93. PubMed ID: 15296838
    [Abstract] [Full Text] [Related]

  • 4. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):155-61. PubMed ID: 15790539
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.
    Neurobiol Dis; 2006 May 24; 22(2):421-34. PubMed ID: 16480889
    [Abstract] [Full Text] [Related]

  • 6. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.
    J Pharm Pharmacol; 2004 May 24; 56(5):649-54. PubMed ID: 15142343
    [Abstract] [Full Text] [Related]

  • 7. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
    Smith AD, Kozlowski DA, Bohn MC, Zigmond MJ.
    Exp Neurol; 2005 Jun 24; 193(2):420-6. PubMed ID: 15869944
    [Abstract] [Full Text] [Related]

  • 8. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
    Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F.
    J Neurochem; 2005 Apr 24; 93(1):94-104. PubMed ID: 15773909
    [Abstract] [Full Text] [Related]

  • 9. R-apomorphine protects against 6-hydroxydopamine-induced nigrostriatal damage in rat.
    Yuan H, Liang LW, Chen ZJ, Ji HR, Wang MK, Zhang HY, Li C, Xu JY.
    Neurosci Bull; 2006 Nov 24; 22(6):331-8. PubMed ID: 17690718
    [Abstract] [Full Text] [Related]

  • 10. Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra.
    Robinson TE, Noordhoorn M, Chan EM, Mocsary Z, Camp DM, Whishaw IQ.
    Synapse; 1994 May 24; 17(1):16-25. PubMed ID: 8042143
    [Abstract] [Full Text] [Related]

  • 11. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
    Harvey BK, Mark A, Chou J, Chen GJ, Hoffer BJ, Wang Y.
    Brain Res; 2004 Oct 01; 1022(1-2):88-95. PubMed ID: 15353217
    [Abstract] [Full Text] [Related]

  • 12. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, Hamada H, Borlongan CV, Date I.
    Brain Res; 2005 Aug 16; 1053(1-2):10-8. PubMed ID: 16045899
    [Abstract] [Full Text] [Related]

  • 13. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R, Mohapel P, Brundin P, Paul G.
    Behav Brain Res; 2005 Jul 01; 162(1):1-10. PubMed ID: 15922062
    [Abstract] [Full Text] [Related]

  • 14. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984 Jul 01; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 15. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
    Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, Chowdrey HS, Biggs CS, Whitton PS.
    Eur J Neurosci; 2007 Jul 01; 26(2):417-23. PubMed ID: 17650114
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 17. Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
    Metz GA, Piecharka DM, Kleim JA, Whishaw IQ.
    Brain Res; 2004 Nov 05; 1026(1):126-35. PubMed ID: 15476704
    [Abstract] [Full Text] [Related]

  • 18. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
    Reglodi D, Lubics A, Tamás A, Szalontay L, Lengvári I.
    Behav Brain Res; 2004 May 05; 151(1-2):303-12. PubMed ID: 15084446
    [Abstract] [Full Text] [Related]

  • 19. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
    Kreisler A, Duhamel A, Vanbesien-Mailliot C, Destée A, Bordet R.
    Behav Pharmacol; 2010 May 05; 21(3):194-205. PubMed ID: 20440202
    [Abstract] [Full Text] [Related]

  • 20. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B, Relova JL, Gallego R, Ben-Batalla I, Perez-Fernandez R.
    J Neurosci Res; 2009 Feb 15; 87(3):723-32. PubMed ID: 18816795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.